Paige Raises $45 Million for Cancer Detection through AI and Computer Vision
Paige, the leader in computational pathology transforming the diagnosis and treatment of cancer, immediately introduced it has closed its Sequence B funding spherical of $45 million, bringing the Firm’s total capital raised to over $70 million. Healthcare Venture Partners introduced the most significant contribution to the round, with Breyer Capital, Kenan Turnacioglu, and different funds collaborating. Paige will use this new capital to drive FDA clearance of its products and widen its portfolio, delving deeper into most cancers pathology, novel biomarkers, and prognostic capabilities. Moreover, the Company will expedite commercial trials within the U.S. and expansion in Brazil, Europe, and Canada.
The corporate additionally grew its digital slide archive to more than 1.2 million pictures and is growing programs to mix digital slides with genomic, drug response. Outcome data to create robust new diagnostic solutions.
Paige is continuing its mission to create and ship advanced computational diagnostics for pathologists and oncologists. These have been shown to work effectively throughout different slide preparation methodologies, and the scanners used to digitize the pictures. And the corporate plans to partner with companies like Philips to bring Paige’s expertise to doctors around the world.